Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Lenalidomide Overcomes Poor Prognosis Conferred by del13q and t(4;14) but Not del17p13 in Multiple Myeloma: Results of the Canadian MM016 Trial.

Nizar J. Bahlis, MD, Kevin Song, MD, Young Trieu, BS, MS, Birgitte Roland, MD, Esther Masih-Khan, PhD, Hong Chang, MD, Helene Bruyere, MD, Adnan Mansoor, MD, Douglas Horsman, MD, Michael Eliasziw, PhD, Douglas Stewart, MD, Donna Reece, MD

Blood (2007) 110 (11): 3597.

https://doi.org/10.1182/blood.V110.11.3597.3597

Published: 2007

Journal Articles

A Tissue Microarray Classification in Multiple Myeloma (MM) Predicts Survival Post Autologous Stem Cell Transplant (ASCT).

Nizar Bahlis, MD, Douglas Stewart, MD, Brian Shin, Adnan Mansoor

Blood (2007) 110 (11): 449.

https://doi.org/10.1182/blood.V110.11.449.449

Published: 2007

Journal Articles

Salvage Thalidomide Improves Survival of Relapsed Multiple Myeloma Patients When Compared to Other Salvage Chemotherapies: A Retrospective Analysis.

Nizar J. Bahlis, MD, Lynn Savoie, MD, Ahsan Chaudhry, MD, Karen Valentine, MD, Deidre Jenkins, MD, Christopher Brown, MD, Jim Russell, MD, Douglas Stewart, MD

Blood (2005) 106 (11): 5144.

https://doi.org/10.1182/blood.V106.11.5144.5144

Published: 2005

Journal Articles

Adult Matched Sibling Blood Cell Transplants (BCT) after Myeloablative Conditioning Incorporating Daily Intravenous (IV) Busulfan (BU) and Low-Dose Antithymocyte Globulin (ATG): Outcomes with Particular Respect to Transplant-Related Mortality (TRM) in 140 Patients.

James A. Russell, FRCP, Ahsan M. Chaudhy, MD, Oluyeme Jeje, MD, Diana Quinlan, RN, Douglas Stewart, MD, Donald Morris, MD, Nizhar J. Bahlis, MD, Lynne Savoie, MD, Christopher B. Brown, MD, Loree Larratt, MD, Michelle Geddes, MD, A. Robert Turner, MD

Blood (2004) 104 (11): 2313.

https://doi.org/10.1182/blood.V104.11.2313.2313

Published: 2004

Journal Articles

Adult Recipients of Matched Related Donor Blood Cell Transplants (BCT) Given Pretransplant Low-Dose Antithymocyte Globulin (ATG) Have Less Chronic Graft-Versus-Host Disease (cGVHD) and Transplant-Related Mortality (TRM): A Matched Pair Analysis.

James A. Russell, FRCPE, A. Robert Turner, MD3, Loree Larratt, MD, Ahsan M. Chaudhry, MD, Oluyeme Jeje, MD, Don Morris, MD, Christopher B. Brown, MD, Lynne Savoie, MD, Nizhar Bahlis, MD, Diana Quinlan, RN, Douglas Stewart, MD

Blood (2004) 104 (11): 2250.

https://doi.org/10.1182/blood.V104.11.2250.2250

Published: 2004

NARROW

Lenalidomide Overcomes Poor Prognosis Conferred by del13q and t(4;14) but Not del17p13 in Multiple Myeloma: Results of the Canadian MM016 Trial.

A Tissue Microarray Classification in Multiple Myeloma (MM) Predicts Survival Post Autologous Stem Cell Transplant (ASCT).

Salvage Thalidomide Improves Survival of Relapsed Multiple Myeloma Patients When Compared to Other Salvage Chemotherapies: A Retrospective Analysis.

Adult Matched Sibling Blood Cell Transplants (BCT) after Myeloablative Conditioning Incorporating Daily Intravenous (IV) Busulfan (BU) and Low-Dose Antithymocyte Globulin (ATG): Outcomes with Particular Respect to Transplant-Related Mortality (TRM) in 140 Patients.

Adult Recipients of Matched Related Donor Blood Cell Transplants (BCT) Given Pretransplant Low-Dose Antithymocyte Globulin (ATG) Have Less Chronic Graft-Versus-Host Disease (cGVHD) and Transplant-Related Mortality (TRM): A Matched Pair Analysis.

Email alerts

ASH Publications

American Society of Hematology

Lenalidomide Overcomes Poor Prognosis Conferred by del13q and t(4;14) but Not del17p13 in Multiple Myeloma: Results of the Canadian MM016 Trial.

A Tissue Microarray Classification in Multiple Myeloma (MM) Predicts Survival Post Autologous Stem Cell Transplant (ASCT).

Salvage Thalidomide Improves Survival of Relapsed Multiple Myeloma Patients When Compared to Other Salvage Chemotherapies: A Retrospective Analysis.

Adult Matched Sibling Blood Cell Transplants (BCT) after Myeloablative Conditioning Incorporating Daily Intravenous (IV) Busulfan (BU) and Low-Dose Antithymocyte Globulin (ATG): Outcomes with Particular Respect to Transplant-Related Mortality (TRM) in 140 Patients.

Adult Recipients of Matched Related Donor Blood Cell Transplants (BCT) Given Pretransplant Low-Dose Antithymocyte Globulin (ATG) Have Less Chronic Graft-Versus-Host Disease (cGVHD) and Transplant-Related Mortality (TRM): A Matched Pair Analysis.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only